Today, WuXi App (Shanghai) announced the acquisition of CRELUX GmbH from Martinsried near Munich. With the acquisition, the globally acting pharma company strengthens its competencies in the structure-based drug development and establishes its first research subsidy in Europe.
WuXi AppTex is a globally leading research and development service provider for the pharma, biotech, and medical device sector. It has now 22 subsidies in the United States and China and about 10,000 employees. CRELUX is a specialist for structure-guided drug development. The integration of CRELUX adds technical and scientific expertise to the Chinese pharma company and complements existing drug development capacities
With the acquisition of the company based in the Innovation and Start-up Center for Biotechnology (IZB), WuXi AppTec choses Martinsried as its European location.
CRELUX GmbH was founded in 2005. For over 10 years, the specialist for structure-guided drug development has provided research companies with tailored and efficient solutions to accelerated drug development. This includes support for early development stages, for example hit generation, hit-to-lead optimisation and services like protein production, biophysical drug interactions studies, fragment-based screening and X-ray crystallography.
"Adding Crelux's expertise and technologies onto more comprehensive, integrated discovery services has always been a main strategic goal for us, “ said Michael Schaeffer, co-founder, business and strategy executive director of Crelux. “With WuXi AppTec we have found the perfect match,” Dr Steve Yang, Executive Vice President und Chief Operating Officer von WuXi AppTec, commented: “For existing and new costumers, the acquisition of CRELUX by WuXi AppTec will offer a more efficient and improved service.”